FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023599285> ?p ?o ?g. }

• W2023599285 endingPage "2408" @default.
• W2023599285 startingPage "2399" @default.
• W2023599285 abstract "Objective:We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).Methods:This study included patients (≥40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100 mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100 mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100 mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10 mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored.Results:There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n = 120) and celecoxib 200 mg (n = 119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were −1.63 mm (−5.37, 2.10), −1.32 mm (−4.88, 2.23), and −1.09 mm (−5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment.Conclusions:Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated.Clinical trial registration:NCT01554163." @default.
• W2023599285 created "2016-06-24" @default.
• W2023599285 creator A5004670805 @default.
• W2023599285 creator A5012945820 @default.
• W2023599285 creator A5015197832 @default.
• W2023599285 creator A5021739236 @default.
• W2023599285 creator A5026999712 @default.
• W2023599285 creator A5028044717 @default.
• W2023599285 creator A5030248447 @default.
• W2023599285 creator A5030261450 @default.
• W2023599285 creator A5031909866 @default.
• W2023599285 creator A5033876965 @default.
• W2023599285 creator A5038612388 @default.
• W2023599285 creator A5050915527 @default.
• W2023599285 creator A5052028390 @default.
• W2023599285 creator A5054304061 @default.
• W2023599285 creator A5054980047 @default.
• W2023599285 creator A5067066167 @default.
• W2023599285 creator A5070539482 @default.
• W2023599285 creator A5077477208 @default.
• W2023599285 creator A5090693306 @default.
• W2023599285 creator A5091699249 @default.
• W2023599285 date "2014-09-03" @default.
• W2023599285 modified "2023-10-16" @default.
• W2023599285 title "Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial" @default.
• W2023599285 cites W1699088132 @default.
• W2023599285 cites W1970213560 @default.
• W2023599285 cites W2012920835 @default.
• W2023599285 cites W2047366874 @default.
• W2023599285 cites W2058139653 @default.
• W2023599285 cites W2062159035 @default.
• W2023599285 cites W2081654187 @default.
• W2023599285 cites W2102272680 @default.
• W2023599285 cites W2103796156 @default.
• W2023599285 cites W2109525472 @default.
• W2023599285 cites W2117896603 @default.
• W2023599285 cites W2124379146 @default.
• W2023599285 cites W2124433729 @default.
• W2023599285 cites W2125487628 @default.
• W2023599285 cites W2133124720 @default.
• W2023599285 cites W2139776244 @default.
• W2023599285 cites W2140215285 @default.
• W2023599285 cites W2158131645 @default.
• W2023599285 cites W2165638511 @default.
• W2023599285 cites W2330496155 @default.
• W2023599285 cites W4245703231 @default.
• W2023599285 doi "https://doi.org/10.1185/03007995.2014.955169" @default.
• W2023599285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25133963" @default.
• W2023599285 hasPublicationYear "2014" @default.
• W2023599285 type Work @default.
• W2023599285 sameAs 2023599285 @default.
• W2023599285 citedByCount "10" @default.
• W2023599285 countsByYear W20235992852016 @default.
• W2023599285 countsByYear W20235992852017 @default.
• W2023599285 countsByYear W20235992852018 @default.
• W2023599285 countsByYear W20235992852020 @default.
• W2023599285 crossrefType "journal-article" @default.
• W2023599285 hasAuthorship W2023599285A5004670805 @default.
• W2023599285 hasAuthorship W2023599285A5012945820 @default.
• W2023599285 hasAuthorship W2023599285A5015197832 @default.
• W2023599285 hasAuthorship W2023599285A5021739236 @default.
• W2023599285 hasAuthorship W2023599285A5026999712 @default.
• W2023599285 hasAuthorship W2023599285A5028044717 @default.
• W2023599285 hasAuthorship W2023599285A5030248447 @default.
• W2023599285 hasAuthorship W2023599285A5030261450 @default.
• W2023599285 hasAuthorship W2023599285A5031909866 @default.
• W2023599285 hasAuthorship W2023599285A5033876965 @default.
• W2023599285 hasAuthorship W2023599285A5038612388 @default.
• W2023599285 hasAuthorship W2023599285A5050915527 @default.
• W2023599285 hasAuthorship W2023599285A5052028390 @default.
• W2023599285 hasAuthorship W2023599285A5054304061 @default.
• W2023599285 hasAuthorship W2023599285A5054980047 @default.
• W2023599285 hasAuthorship W2023599285A5067066167 @default.
• W2023599285 hasAuthorship W2023599285A5070539482 @default.
• W2023599285 hasAuthorship W2023599285A5077477208 @default.
• W2023599285 hasAuthorship W2023599285A5090693306 @default.
• W2023599285 hasAuthorship W2023599285A5091699249 @default.
• W2023599285 hasConcept C126322002 @default.
• W2023599285 hasConcept C141071460 @default.
• W2023599285 hasConcept C14184104 @default.
• W2023599285 hasConcept C142724271 @default.
• W2023599285 hasConcept C168563851 @default.
• W2023599285 hasConcept C197934379 @default.
• W2023599285 hasConcept C203092338 @default.
• W2023599285 hasConcept C204787440 @default.
• W2023599285 hasConcept C2776164576 @default.
• W2023599285 hasConcept C2776214540 @default.
• W2023599285 hasConcept C2776467144 @default.
• W2023599285 hasConcept C2779286237 @default.
• W2023599285 hasConcept C42219234 @default.
• W2023599285 hasConcept C535046627 @default.
• W2023599285 hasConcept C71924100 @default.
• W2023599285 hasConceptScore W2023599285C126322002 @default.
• W2023599285 hasConceptScore W2023599285C141071460 @default.
• W2023599285 hasConceptScore W2023599285C14184104 @default.
• W2023599285 hasConceptScore W2023599285C142724271 @default.
• W2023599285 hasConceptScore W2023599285C168563851 @default.
• W2023599285 hasConceptScore W2023599285C197934379 @default.

• next